Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

This news release also contains forward-looking statements of OSI. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI's and its collaborators' abilities to effectively market and sell Tarceva and to expand the
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... Sunday 31 August 2014: A new batteryless cardiac ... by heart motion was presented at ESC Congress ... prototype device does not require battery replacement. , ... Engineering Group at ARTORG, University of Bern, Switzerland, ... medical implants. Once they reach a critically low ...
(Date:8/30/2014)... In a world where a typical response to conflict ... launches a game app to teach another way. Launched ... app is a colorful way to encourage moral values playfully. ... pulls double-duty by teaching players new ways to find happiness ... gamers for consistently taking the high road, the Ultimate Karma ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 The ... modeling the body that will reveal to users some shocking ... lead to great results in modeling looks, as well as ... the new method says that there is one unique trick ... new method indicates that despite what many people might think, ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) (Pink Sheets: ... with physicians,today announced that its board of directors has ... of the Company,s outstanding Common Stock., The shares ... market price.,The purchases will be made at the Company,s ...
... (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ), What: HCA ... 2008 @ 9:00 am CT, Where: http://www.videonewswire.com/event.asp?id=52343 , ... log on to the web at the ... HCA Healthcare, 615-344-2688, ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ("China Sky ... ), a,leading fully integrated pharmaceutical company producing over-the-counter,drugs ... today that it,recently obtained production approval from the ... two of its newly developed drugs., Sodium ...
... ANGELES, Oct. 30 Cardo Medical, a company ... the FDA 510k,clearance of its Align 360 Total ... planned for commercial release during the second quarter ... the flagship product within,its Align 360 platform which ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Oct. 30 ADVENTRX Pharmaceuticals,Inc. ... conference call with,simultaneous webcast to discuss third quarter 2008 results on ... Mark N. K.,Bagnall, Executive Vice President and Chief Financial Officer, is ...
... and David,Simon, M.D. in Southern California helps people find relief from stress ... ... investments., SAN DIEGO, Oct. 30 As ... life savings,The Chopra Center for Wellbeing is teaching those impacted how to ...
Cached Medicine News:Health News:Phyhealth Announces Stock Buyback Program 2Health News:Phyhealth Announces Stock Buyback Program 3Health News:China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 2Health News:Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System 3Health News:Turbulent Times Turn The Chopra Center Into Mecca for Calm 2
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... CB1,antagonist rimonabant to show benefits beyond weight reduction ... | March 08, 2007 | The Business Intelligence,firm ... antagonist Acomplia (rimonabant) has at least,five competitors in ... more,in earlier phases of R&D. While Acomplia received ...
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
Cached Medicine Technology:Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 2Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success 3Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2
... The Leica M520 OH3 ... the best optical performance available ... innovative and unique stand. The ... lightest, has the greatest range ...
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
PS Medical lumboperitoneal catheter systems are designed to divert CSF from the lumbar subarachnoid space to the peritoneal cavity, using simplified surgical techniques....
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Medicine Products: